

Cancer type	Statin	Concurrent therapy	Statin dose	Statin schedule	# patients	Response	Ref
Various	Lovastatin	N/A	2 to 45 mg/kg/day	4 x per day, monthly cycles of 7 days dosing	56	1 PR (2%)	[34]
Various	Fluvastatin	N/A	2 to 8 mg/kg/day	1 x per day, monthly cycles of 14 days drug,	12	2 PR (17%)	[35]
Gastric	Lovastatin	N/A	35 mg/kg/day	Split across 4x per day, 7 days, monthly cycles	14	1 SD (7%)	[36]
Hepatocellular carcinoma	Pravastatin	Prior TAE + 5FU	0 or 40 mg	1 x per day for 16 months	41 statin, 42 placebo	OS 19 months (Pravastatin) v 9 months (placebo) P=0.006	[8]
Head and neck squamous cell carcinoma	Lovastatin	N/A	5 to 7.5mg/kg/day	Explored several up to cycles of 21 days on, 7 days off, split across 4 x per day	22	6 SD (27%)	[37]
Various	Lovastatin	N/A	10 to 415mg/m ²	Every 6h, for 4 days, 24 days off, 1-6 cycles	32	4 SD (13%)	[38]
Myeloma, lymphoma	Simvastatin	Vincristine, doxorubicin, dexamethasone or cyclophosphamide, vincristine, doxorubicin, prednisolone.	5 to 15 mg/kg/day	Spilt across 2 doses for 7 days, prior to chemotherapy	28	1 CR (4%), 3 PR (11%), 3 MR (3%), 5 SD (18%)	[39]

Myeloma, lymphoma	Simvastatin	Vincristine, doxorubicin, dexamethasone	15 mg/kg/day	Spilt across 2 doses, 2-4 cycles of 7 days on, 21 days off	12	1 PR (8%), 6 SD (50%)	[40]
Multiple myeloma (chemotherapy resistant)	Simvastatin	Bortezomib, bendamustine	80 mg/day	Once daily, 5 days	6	5/6 (83%) show decreased paraprotein	[41]
Gastric	Pravastatin	TACE	0 or 20-40 mg/day	Once daily	131 TACE only 52 TACE & pravastatin	Increased OS 20.9 months (statin) versus 12 months (placebo) $P=0.003$	[9]
Brain stem tumours	Fluvastatin	Carboplatin, vincristine, thalidomide; radiotherapy	8mg/kg/day	1 x per day, 4 cycles of 28 days with statin days 1-14	9	7 PR (78%)	[42]
Multiple myeloma	Simvastatin	Various	15 mg/kg/day	Split across 2 doses, 2 cycles of 7days drug +21 days off	6	Study terminated early due to osteoclast activity	[43]
Colorectal	Simvastatin	Irinotecan, 5FU, leucovorin	40 mg/day	Once daily	49	Response rate comparable to historical studies of chemotherapy alone	[44]
Gastric	Pravastatin	Epirubicin, capecitabine, cisplatin	0 or 40 mg/day	Once daily	14 statin, 14 placebo	Response rate not increased by statin, study terminated	[45]

						before further accrual	
Non-small cell lung cancer	Simvastatin	Gefitinib	40 mg/day	Once daily	54 gefitinib & simvastatin, 52 gefitinib only	OS 13.6 months (gefitinib & simvastatin) v 12 months (gefitinib alone), P>0.05	[46]
Non-small cell lung cancer	Simvastatin	Irinotecan, cisplatin	40 mg/day	Once daily	56	42 PR (75%), 10 SD (18%) - not different to historical data	[47]
Pancreatic	Simvastatin	Gemcitabine	0 or 40mg/day	Once daily	58 gemcitabine & simvastatin 56 gemcitabine	1 year OS 27% (gemcitabine & simvastatin), OS 20% (gemcitabine alone) P>0.05	[48]
Colorectal (Kras mutant)	Simvastatin	Cetuximab, irinotecan	80 mg/day	Once daily	47	1 PR (2%), 33 SD (70%)	[49]
Acute myeloid leukemia	Pravastatin	Idarubicine, cytarabine	1280 mg/day	Once daily	36	20 CR (56%), 7 CRi (19%), significantly different from historical data P<0.05	[10]
Gastric	Simvastatin	Capecitabine, cisplatin	0 or 40 mg/day	Once daily	120 statin, 124 placebo	1 year survival 47.9 m (simvastatin) vs 47.7 m (placebo)	[50]
MDS	Atorvastatin	Idarubicin, cytarabine	1280 mg/day	Once daily	24	15 CR (63%), but didn't meet	[16]

						70% CR rate criteria to continue study.	
Colorectal (Kras mutant)	Simvastatin	Panitumumab		Once daily	14	1 (7%) patient durable PFS but didn't meet criteria to continue study.	[51]
Colorectal	Simvastatin	Irinotecan, leucovorin, 5FU or irinotecan, capecitabine	0 or 40 mg/day	Once daily	134 statin, 135 placebo	OS 15.9 m (simvastatin), 19.9 m (placebo), P>0.05	[52]
Colorectal (Kras mutant)	Simvastatin	Cetuximab	80 mg/day	Once daily	18	4 (22%) increased PFS but didn't meet criteria to continue study	[53]
Various	Rosuvastatin	Erlotinib	1- 2 mg/kg/day	Statin given daily 2 or 3 weeks; dose divided between and 4 times according to dose level.	22	4 (18%) SD	[15]
Brain metastases from various tissue	Simvastatin	Radiation	0 or 80 mg/day	Once daily	50	1 year survival 8 % (statin), vs 12% (control) P > 0.05	[54]
Small cell lung cancer	Pravastatin	Etoposide + cisplatin or carboplatin radiotherapy	40 mg/day	Once daily	410 statin, 409 placebo	OS 10.7 m (statin), 10.6 m (placebo)	[11]

Table 1 A search of Pubmed for clinical trials containing the terms “statin” and “cancer” led to the identification of 27 reports. The table summarizes the type of cancer in which the statin was evaluated, the dosing regimen of the statin and the outcome. Trials which included a placebo arm are those in which dose is also reported as 0 mg/day. CR, complete response; PR, partial response; SD, stable disease; OS, overall survival; PFS, progression-free survival, TACE, transarterial chemoembolization.